Warning

References

  1. FSRH Clinical Effectiveness Unit. FSRH Clinical Guideline: Progestogen-only Implant [Internet]. The Faculty of Sexual and Reproductive Healthcare; 2021 Feb [cited 2022 March 14]. Available from: https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-implants-feb-2014/
  2. FSRH Clinical Effectiveness Unit. UK Medical Eligibility Criteria for Contraceptive Use [Internet]. The Faculty of Sexual and Reproductive Healthcare; 2016 Apr [updated 2019 Sep; cited cited 2022 March 14]. Available from: https://www.fsrh.org/documents/ukmec-2016/
  3. FSRH Clinical Effectiveness Unit. FSRH Clinical Guideline: Problematic Bleeding with Hormonal Contraception [Internet]. The Faculty of Sexual and Reproductive Healthcare; 2015 http://www.fsrh.org/pdfs/CEUGuidanceProblematicBleedingHormonalContraception.pdf accessed [cited 2022 March 14]
  4. FSRH Clinical Effectiveness Unit. FSRH Guidance: Drug Interactions with Hormonal Contraception [Internet]. The Faculty of Sexual and Reproductive Healthcare; 2022 May [cited 2022 March 14]. https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/
  5. FSRH Clinical Effectiveness Unit Statement: Management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants [Internet] 2017 March https://www.fsrh.org/documents/fsrh-guidance-fsrh-guidance-management-of-women-taking/ [cited 2022 March 14] 

Editorial Information

Last reviewed: 31/05/2022

Next review date: 31/05/2024

Author(s): West of Scotland Managed Clinical Network for Sexual Health Clinical Guidelines Group .

Version: 8.1

Approved By: West of Scotland Managed Clinical Network for Sexual Health